Company Announcements
August 4, 2021

Resignation of Chairman – Peter Turvey

Melbourne, Australia 4 August 2021 – – ImmVirX Pty Limited, a company developing novel oncolytic immunotherapy combinations, today advises that Mr Peter Turvey has resigned as Chairman of the company due to ill health.

On behalf of the Board, ImmVirX Managing Director Dr Malcolm McColl thanks Mr Turvey for his exceptional contribution to the company through its foundational period. He has a long working history with many of the ImmVirX team, having previously served on the board of Viralytics Limited from 2014 until it was acquired by Merck and Co. in 2018.

Dr McColl said: “Peter has provided remarkable service to the Australian biopharmaceutical and biotechnology industry for over 30 years. In recent times he was an integral part of the success of Viralytics and played an important role in the establishment and journey to date at ImmVirX. We will miss his wise counsel, energy and passion for oncology drug development. My colleagues from Viralytics and ImmVirX are extremely grateful for his thoughtful, experienced advice, guidance and friendship over many years and thank him for his highly valued contribution.”

Mr Turvey served as Chairman of ImmVirX since its inception in 2019. In the interim period before a new appointment Dr McColl will serve as Acting Chairman.

About ImmVirX

ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations. Its novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses. 
The proprietary bio-selected RNA viruses target specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.   
In this way, the viral candidates are intended to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, pancreatic and ovarian cancer.

Media Contact

Dr. Malcolm McColl

Acting Chairman, Chief Executive Officer and Co-Founder  

Ph: +61 (0)478 202 372


Continue reading

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect